苏州长征-欣凯制药

Suzhou Changzheng-Xinkai Pharmaceutical is a Chinese pharmaceutical company specializing in the research, development, and manufacturing of small molecule therapeutics, particularly focusing on autoimmune and inflammatory diseases. Originally established in 2000 as a joint venture between Jiangsu Wuzhong Pharmaceutical Group and US-based Cinkate, the company was fully acquired by Cinkate Pharmaceutical in 2023. Its flagship commercial product, Airohua (leflunomide), was the first Class 1 innovative drug approved in China for rheumatoid arthritis and lupus nephritis. The company operates a high-standard GMP-certified manufacturing facility in Suzhou, which serves as the industrialization platform for Cinkate's innovative pipeline, including candidates for secondary hyperparathyroidism, chronic hepatitis B, and solid tumors.